BEYFORTUS

This brand name is authorized in Austria, Canada, Estonia, Spain, France, Croatia, Ireland, Italy, Lithuania, Romania, United States

Active ingredients

The drug BEYFORTUS contains one active pharmaceutical ingredient (API):

1 Nirsevimab UNII VRN8S9CW5V - NIRSEVIMAB

Nirsevimab is a recombinant neutralising human IgG1ĸ long-acting monoclonal antibody to the prefusion conformation of the RSV F protein which has been modified with a triple amino acid substitution (YTE) in the Fc region to extend serum half-life. Nirsevimab inhibits the essential membrane fusion step in the viral entry process, neutralising the virus and blocking cell-to-cell fusion. Read about Nirsevimab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
BEYFORTUS Solution for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J06BD08		J Antiinfectives for systemic use → J06 Immune sera and immunoglobulins → J06B Immunoglobulins → J06BD Antiviral monoclonal antibodies
Discover more medicines within J06BD08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02537206, 02537214
Country: EE	Ravimiamet	Identifier(s): 1893405, 1893427, 1893438, 1893449
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1221689001, 1221689004
Country: FR	Base de données publique des médicaments	Identifier(s): 62438151, 65150617
Country: IT	Agenzia del Farmaco	Identifier(s): 050403017, 050403029, 050403031, 050403043, 050403056, 050403068
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1095796, 1095797, 1095798, 1095799, 1095800, 1095801
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W69258001, W69258002, W69258003, W69259001, W69259002, W69259003
Country: US	FDA, National Drug Code	Identifier(s): 49281-574, 49281-575